• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

ROMIDEPSIN Drug Record

  • Summary
  • Interactions
  • Claims
  • ROMIDEPSIN chembl:CHEMBL343448 ApprovedAntineoplastic

    Alternate Names:

    DEPSIPEPTIDE
    ISTODAX
    ROMIDEPSIN
    FR-901228
    FK-228
    NSC-630176
    CHROMADAX
    ANTIBIOTIC FR 901228
    ISTODAX®
    FR901228
    FK228
    chemidplus:128517-07-7
    chembl:CHEMBL343448
    pubchem.compound:5352062
    rxcui:877510

    Drug Info:

    Drug Class antineoplastic agents
    Year of Approval 2009
    FDA Approval Cutaneous T-cell lymphoma, Peripheral T-cell lymphoma
    Drug Class Small molecule inhibitor
    FDA Approval approved
    Drug Class small molecule
    Drug Indications antineoplastic agent
    (9 More Sources)

    Publications:

    VanderMolen et al., 2011, Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma., J. Antibiot.
    Yao Y et al., 2015, Discovery of Novel Class I Histone Deacetylase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities., J Med Chem
    Yu et al., 2002, Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228., J. Natl. Cancer Inst.
    Cruickshank et al., 2017, Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin., Leukemia
    Khan et al., 2004, Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma., Br. J. Haematol.
    Sato et al., 2004, FR901228, a novel histone deacetylase inhibitor, induces cell cycle arrest and subsequent apoptosis in refractory human pancreatic cancer cells., Int. J. Oncol.
    Zhu et al., 2001, Increased expression of unmethylated CDKN2D by 5-aza-2'-deoxycytidine in human lung cancer cells., Oncogene
    Nguyen et al., 2004, Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells., Clin. Cancer Res.
    Weiser et al., Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1., J. Immunother.
  • ROMIDEPSIN   CTAG1B

    Interaction Score: 6.51

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11265773


    Sources:
    NCI

  • ROMIDEPSIN   CDKN2D

    Interaction Score: 6.51

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11753657


    Sources:
    NCI

  • ROMIDEPSIN   HDAC6

    Interaction Score: 0.5

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name Depsipeptide
    Mechanism of Interaction Histone deacetylase inhibitor

    PMIDs:
    21587264 26331334


    Sources:
    DTC TdgClinicalTrial ChemblInteractions TEND

  • ROMIDEPSIN   HDAC1

    Interaction Score: 0.48

    Interaction Types & Directionality:
    antagonist (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Notes
    Mechanism of Interaction Histone deacetylase inhibitor
    Direct Interaction yes

    PMIDs:
    21587264


    Sources:
    TALC MyCancerGenome TdgClinicalTrial ChemblInteractions TEND TTD

  • ROMIDEPSIN   HDAC2

    Interaction Score: 0.42

    Interaction Types & Directionality:
    antagonist (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Notes
    Mechanism of Interaction Histone deacetylase inhibitor
    Direct Interaction yes

    PMIDs:
    21587264


    Sources:
    TALC TdgClinicalTrial ChemblInteractions TEND

  • ROMIDEPSIN   CDKN1A

    Interaction Score: 0.36

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15014036


    Sources:
    NCI

  • ROMIDEPSIN   HDAC8

    Interaction Score: 0.35

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes
    Mechanism of Interaction Histone deacetylase inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    TALC TdgClinicalTrial ChemblInteractions TEND

  • ROMIDEPSIN   HDAC3

    Interaction Score: 0.34

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name Depsipeptide
    Novel drug target Established target
    Notes

    PMIDs:
    None found


    Sources:
    TALC TdgClinicalTrial ChemblInteractions TEND

  • ROMIDEPSIN   HDAC4

    Interaction Score: 0.33

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Histone deacetylase inhibitor
    Trial Name Depsipeptide

    PMIDs:
    21587264


    Sources:
    MyCancerGenome TdgClinicalTrial ChemblInteractions

  • ROMIDEPSIN   HDAC7

    Interaction Score: 0.28

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Histone deacetylase inhibitor
    Direct Interaction yes
    Trial Name Depsipeptide

    PMIDs:
    None found


    Sources:
    MyCancerGenome TdgClinicalTrial ChemblInteractions

  • ROMIDEPSIN   HDAC11

    Interaction Score: 0.22

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name Depsipeptide
    Novel drug target Established target
    Mechanism of Interaction Histone deacetylase inhibitor

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial ChemblInteractions

  • ROMIDEPSIN   HDAC9

    Interaction Score: 0.2

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name Depsipeptide
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    MyCancerGenome TdgClinicalTrial

  • ROMIDEPSIN   HDAC10

    Interaction Score: 0.2

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Histone deacetylase inhibitor
    Direct Interaction yes
    Trial Name Depsipeptide

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial ChemblInteractions

  • ROMIDEPSIN   HDAC5

    Interaction Score: 0.19

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name Depsipeptide
    Mechanism of Interaction Histone deacetylase inhibitor

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial ChemblInteractions

  • ROMIDEPSIN   BIRC5

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14767553


    Sources:
    NCI

  • ROMIDEPSIN   MCL1

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15059137


    Sources:
    NCI

  • ROMIDEPSIN   KMT2A

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Preclinical - Cell line xenograft
    Response Type sensitive

    PMIDs:
    27443263


    Sources:
    JAX-CKB

  • ROMIDEPSIN   ERBB2

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11929951


    Sources:
    NCI

  • ROMIDEPSIN   KRAS

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Preclinical
    Response Type sensitive

    PMIDs:
    None found


    Sources:
    JAX-CKB

  • MyCancerGenome: ROMIDEPSIN

    • Version: 20-Jun-2017

    Alternate Names:
    ISTODAX Trade Name

    Drug Info:
    Drug Class Small molecule inhibitor
    FDA Approval Cutaneous T-cell lymphoma, Peripheral T-cell lymphoma

    Publications:

  • TEND: ROMIDEPSIN

    • Version: 01-August-2011

    Alternate Names:
    ROMIDEPSIN Primary Drug Name

    Drug Info:
    Year of Approval 2009
    Drug Class antineoplastic agents

    Publications:

  • TdgClinicalTrial: ROMIDEPSIN

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antineoplastic agent
    Drug Class small molecule
    FDA Approval approved

    Publications:

  • NCI: FR901228

    • Version: 14-September-2017

    Alternate Names:
    C1544 NCI drug code

    Drug Info:

    Publications:
    Yu et al., 2002, Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228., J. Natl. Cancer Inst.
    Sato et al., 2004, FR901228, a novel histone deacetylase inhibitor, induces cell cycle arrest and subsequent apoptosis in refractory human pancreatic cancer cells., Int. J. Oncol.
    Weiser et al., Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1., J. Immunother.

  • NCI: DEPSIPEPTIDE

    • Version: 14-September-2017

    Alternate Names:
    C1544 NCI drug code

    Drug Info:

    Publications:
    Yu et al., 2002, Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228., J. Natl. Cancer Inst.
    Khan et al., 2004, Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma., Br. J. Haematol.
    Nguyen et al., 2004, Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells., Clin. Cancer Res.

  • DTC: ROMIDEPSIN

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL1213490 ChEMBL Drug ID

    Drug Info:

    Publications:
    Yao Y et al., 2015, Discovery of Novel Class I Histone Deacetylase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities., J Med Chem

  • JAX-CKB: Romidepsin

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Cruickshank et al., 2017, Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin., Leukemia

  • JAX-CKB: romidepsin

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Cruickshank et al., 2017, Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin., Leukemia

  • TALC: ROMIDEPSIN

    • Version: 12-May-2016

    Alternate Names:
    ROMIDEPSIN Primary Drug Name
    ROMIDEPSIN Drug Generic Name
    ISTODAX Drug Trade Name

    Drug Info:

    Publications:

  • TTD: Romidepsin

    • Version: 2020.06.01

    Alternate Names:
    D0L7LC TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL343448

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL1213490

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

  • TALC: FK-228

    • Version: 12-May-2016

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21